Literature DB >> 12027126

Mitral valve repair in redo cardiac surgery.

D H Adams1, F Filsoufi, J G Byrne, A N Karavas, L Aklog.   

Abstract

An increasing number of patients are being referred for mitral valve repair in the redo cardiac surgery setting. The most common clinical scenarios involve prior coronary bypass surgery or aortic valve replacement, each presenting special challenges in terms of gaining valve exposure to enable repair while limiting dissection as much as possible. A right anterior thoracotomy approach is preferred in most patients, coupled with hypothermic fibrillatory arrest. A repeat sternotomy may be favored in select circumstances such as when there is a need for bypass grafting or moderate aortic insufficiency is present. Special attention to cannulation techniques, perfusion conditions, valve exposure, and de-airing maneuvers are all important to ensure good clinical results. Using a tailored approach we have performed mitral valve repair in 22 patients with a patent left internal mammary artery graft following coronary artery bypass grafting between July 1992 and February 2000 with acceptable morbidity and low mortality.

Entities:  

Mesh:

Year:  2002        PMID: 12027126     DOI: 10.1111/j.1540-8191.2001.tb01218.x

Source DB:  PubMed          Journal:  J Card Surg        ISSN: 0886-0440            Impact factor:   1.620


  2 in total

1.  Suture dehiscence and collagen content in the human mitral and tricuspid annuli.

Authors:  Immanuel David Madukauwa-David; Eric L Pierce; Fatiesa Sulejmani; Joshua Pataky; Wei Sun; Ajit P Yoganathan
Journal:  Biomech Model Mechanobiol       Date:  2018-10-04

2.  Right mini-thoracotomy approach reduces hospital stay and transfusion of mitral or tricuspid valve reoperation with non-inferior efficacy: evidence from propensity-matched study.

Authors:  Qing Wang; Xiaofei Xue; Jie Yang; Qian Yang; Pei Wang; Liaoyuan Wang; Peng Zhang; Suyu Wang; Jing Wang; Jibin Xu; Jian Xiao; Zhinong Wang
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.